Closed-loop in Adults With Type 2 Diabetes
This research is investigating a new system called CamAPS HX, which works like an 'artificial pancreas', for adults living with type 2 diabetes who take insulin. The main goal is to find out if this automated system can help manage blood sugar levels more effectively and safely at home over 26 weeks, compared to their usual insulin treatment with a glucose sensor. The study also checks how easy the new system is for people to use and live with. Researchers will compare key health markers like average blood sugar (HbA1c), how much time blood sugars spend in a healthy range, insulin needs, and any side effects. It involves 224 participants across several countries, including the UK.
En un coup d'œil
De quoi parle cette étude ?
This study is designed to explore a new way of managing type 2 diabetes for adults who rely on insulin. It focuses on a special system called CamAPS HX, which acts like an 'artificial pancreas'. Imagine a smart system that automatically adjusts your insulin based on your blood sugar readings. The main idea is to see if this advanced system can help people keep their blood sugar levels more stable and within a healthy range while they go about their daily lives at home. This is important because good blood sugar control can help prevent long-term health problems associated with diabetes.
The researchers want to compare this new system against the standard care, where people manage their insulin themselves, often with the help of a glucose sensor that shows their blood sugar levels. They will be looking closely at several things: how well the new system controls blood sugar (measured by average blood sugar called HbA1c), how safe it is (checking for very low blood sugar, which can be dangerous), and how practical and easy it is for people to use every day. They'll also compare things like insulin amounts, weight, and general health.
This study builds on previous successful research with similar systems for other types of diabetes. By including 224 volunteers from the UK and other countries, the study aims to gather strong evidence to understand if this new technology could be a valuable tool for adults with type 2 diabetes. Participants will get thorough training on how to use any new equipment safely.
Points clés
- This study explores a new 'artificial pancreas' system (CamAPS HX) for type 2 diabetes.
- It aims to improve blood sugar control at home compared to current insulin treatment.
- Safety and ease of use are key areas of investigation.
- The study involves 224 adults with type 2 diabetes who use insulin.
- Participation lasts about 7 months, including a 26-week treatment period.
Qui peut être éligible ?
To be considered for this study, you need to be an adult aged 18 or over. You must have been diagnosed with type 2 diabetes for at least a year and have been using insulin treatment for at least six months. You should also be taking certain diabetes medications (SGLT2 inhibitors and/or GLP-1 receptor agonists) or have been offered them previously. Your average blood sugar (HbA1c) should be 15% or less. It's important that you are willing to wear the study devices and follow the study instructions, and you must be able to understand and agree to take part.
There are some reasons why you might not be able to join. For example, if you have type 1 diabetes, currently use an insulin pump or another 'closed-loop' system, or have serious health conditions (physical or mental) that might affect the study. If you are pregnant, planning to get pregnant, or breastfeeding, you cannot participate. Also, severe problems with your eyesight or hearing, allergies to insulin or certain glues, serious skin conditions where sensors might be placed, or problems with drug or alcohol abuse would also mean you couldn't take part.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Avez-vous 18 ans ou plus ?
- Have you had type 2 diabetes for at least a year?
- Have you been using insulin for at least six months?
- Do you take SGLT2 inhibitors and/or GLP-1 receptor agonists, or have you been offered them?
- Are you able to agree to take part and follow study instructions?
- Are you not pregnant or planning to be, and not breastfeeding?
En quoi consiste la participation ?
If you join this study, you will first have a 'run-in' period, followed by a 26-week period using either the new CamAPS HX system or your usual insulin treatment with a glucose sensor. Which group you are in will be decided by chance (like flipping a coin). You'll need to wear devices for monitoring your blood sugar. You'll receive training on how to use any new equipment safely. Throughout the 26 weeks, the research team will regularly check your blood sugar levels, insulin use, body weight, and kidney and liver function. They will also ask you to complete questionnaires and have interviews about your experience with the system. The total duration of active participation, including the run-in and intervention period, is about 7 months.
Risques et avantages potentiels
Locations (12)
- University of MelbourneCode postal vérifiéMelbourne, Australie· Pas encore en recrutement
- Medical University of GrazCode postal vérifiéGraz, Autriche· Pas encore en recrutement
- Diabetes Centre, Institute of Clinical and Experimental MedicineCode postal vérifiéPrague, Tchéquie· Pas encore en recrutement
- CHU de ToulouseCode postal vérifiéToulouse, France· Pas encore en recrutement
- Bern University HospitalCode postal vérifiéBern, Switzerland· Pas encore en recrutement
- Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation TrustCode postal vérifiéCambridge, Royaume-Uni· Recrutement
- Royal Derby HospitalCode postal vérifiéDerby, United Kingdom· Pas encore en recrutement
- Leicester Diabetes CentreCode postal vérifiéLeicester, United Kingdom· Recrutement
- Guy's and St Thomas' NHS Foundation TrustCode postal vérifiéLondres, Royaume-Uni· Recrutement
- King's College Hospital, King's College NHS Foundation TrustCode postal vérifiéLondres, Royaume-Uni· Recrutement
- Manchester Royal Infirmary, Central Manchester University Hospitals NHS Foundation TrustCode postal vérifiéManchester, Royaume-Uni· Pas encore en recrutement
- Norfolk and Norwich University HospitalCode postal vérifiéNorwich, United Kingdom· Recrutement
Questions fréquentes
What is an 'artificial pancreas' system?
It's a smart system that automatically adjusts your insulin delivery based on your blood sugar readings, aiming to keep your levels stable.
Will I know if I'm using the new system or my usual treatment?
Yes, this is an 'open-label' study, meaning you will know which treatment you are receiving.
Combien de temps vais-je participer à l'étude ?
After an initial check-up period, you'll be actively involved for about 26 weeks, which is roughly six months.
What is HbA1c?
HbA1c is a blood test that shows your average blood sugar level over the past 2-3 months.
Who is running this study?
The study is being conducted by researchers at several hospitals and universities across the UK and other European countries.
Comment en savoir plus
Charlotte K Boughton, PhD
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Intéressé à participer ?
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.